重大事件
外國發行人報告
6-K
2026-07-10
禾賽科技提交6-K披露股份拆細生效,每1股拆為8股
AI 繁中摘要
Hesai Group (禾賽科技) 提交 6-K 申報,披露股份拆細及相關調整已於 2026 年 7 月 10 日生效。
📌 **股份拆細要點**:
- 每 1 股現有 Class B 普通股拆細為 8 股 Subdivided Class B Ordinary Shares。
- 買賣單位由 20 股改為 100 股,2026 年 7 月 10 日起生效。
- 現有股票證書可用至 2026 年 8 月 17 日下午 4:10,其後須換領新證書(黃色)。
📌 **購股權及 RSU 調整**(按比例調整,不影響整體權益):
- 未行使購股權:總數由 7,717,032 股增至 61,736,256 股,行使價相應調整為原價的 1/8(例如 Cailian Yang 部分期權行使價由 2.10 美元調至 0.2625 美元)。
- 未行使 RSU:總數由 2,186,853 股增至 17,494,824 股,購買價維持零美元。
- 調整已獲公司核數師書面確認符合 2021 年計劃及聯交所規則。
此舉屬技術性調整,不改變股東權益比例,但需留意交易安排及臨時櫃檯運作(2026 年 7 月 10 日至 8 月 13 日,臨時買賣單位為 160 股)。投資者應檢查持股及交易單位變化,避免短暫不便。
展開英文正文
EX-99.1 2 tm2620203d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Hesai Group 禾 賽 科 技 * (A company controlled through weighted voting rights and incorporated in the Cayman Islands with limited liability) (HKEX Stock Code: 2525) (NASDAQ Stock Ticker: HSAI) (1) SHARE SUBDIVISION BECOMING EFFECTIVE ON JULY 10, 2026; AND (2) ADJUSTMENTS TO OUTSTANDING SHARE OPTIONS AND RSUs References are made to the announcement, the circular (the “Circular”) and notice of the annual general meeting (the “AGM”) of Hesai Group (the “Company”) each dated May 26, 2026, in relation to, among others, the Share Subdivision, and the announcement of the Company dated June 26, 2026 in respect of the poll results of the AGM. Unless otherwise required by the context, capitalized terms used in this announcement shall have the same meanings as defined in the Circular. SHARE SUBDIVISION BECOMING EFFECTIVE ON JULY 10, 2026 The Board is pleased to announce that all the conditions of the Share Subdivision have been fulfilled and the Share Subdivision has become effective on Friday, July 10, 2026 (the “Effective Date”). Dealing in the Subdivided Class B Ordinary Shares on the Hong Kong Stock Exchange commences at 9:00 a.m. on Friday, July 10, 2026. Please refer to the Circular for further details of, among others, the trading arrangement, the arrangement for free exchange of Share certificates and matching services for odd lots of the Subdivided Class B Ordinary Shares in connection with the Share Subdivision. Shareholders should note that upon the Share Subdivision becoming effective, the new share certificates of the Subdivided Class B Ordinary Shares will be issued in yellow colour. Upon the Share Subdivision becoming effective, the Existing Share Certificates for the Shares will only be valid for delivery, trading and settlement purposes for the period up to 4:10 p.m. on Monday, August 17, 2026 and thereafter will not be accepted for delivery, trading and settlement purposes. However, the Existing Share Certificates will continue to be good evidence of legal title and may be exchanged for Subdivided Share Certificates for the Subdivided Shares at any time. 1 CHANGE IN BOARD LOT SIZE As a result of the Share Subdivision becoming effective, the Change in Board Lot Size will come into effect on Friday, July 10, 2026. The board lot size of the Class B Ordinary Shares for trading on the Hong Kong Stock Exchange will be changed from 20 existing Class B Ordinary Shares to 100 Subdivided Class B Ordinary Shares. There will be a temporary counter open for trading in temporary board lot of 160 Subdivided Class B Ordinary Shares (in the form of Existing Share Certificates) between 9:00 a.m. on Friday, July 10, 2026 and 4:10 p.m. on Thursday, August 13, 2026. For details of the trading arrangement, please refer to the Circular and the expected timetable therein. ADJUSTMENTS TO OUTSTANDING SHARE OPTIONS AND RSUs Prior to the Share Subdivision becoming effective, there were (i) 7,717,032 outstanding share options granted under the 2021 Plan to subscribe for an aggregate of 7,717,032 existing Class B Ordinary Shares; and (ii) 2,186,853 outstanding RSUs granted under the 2021 Plan representing an aggregate of 2,186,853 underlying existing Class B Ordinary Shares. Upon the Share Subdivision becoming effective, (i) pro-rata adjustments will be made to the exercise prices and the number of outstanding share options and the number of outstanding RSUs which have been granted under the 2021 Plan; and (ii) there will be (a) 61,736,256 outstanding share options granted under the 2021 Plan to subscribe for an aggregate of 61,736,256 Subdivided Class B Ordinary Shares, and (b) 17,494,824 outstanding RSUs granted under the 2021 Plan representing an aggregate of 17,494,824 underlying Subdivided Class B Ordinary Shares. Details of the adjustments to the outstanding share options and the RSUs to be made upon the Share Subdivision becoming effective on Friday, July 10, 2026 are as follows: Adjustments to the Outstanding Share Options Pursuant to the terms and conditions of the 2021 Plan, the exercise price and the number of the outstanding share options granted under the 2021 Plan have been adjusted in the following manner with effect from the Effective Date: Before adjustments After adjustments Number of Existing Number of Class B Ordinary Exercise price Subdivided Shares Exercise price per Shares to be issued per Existing to be issued upon Subdivided upon exercise of Class B exercise of Class B the outstanding Ordinary the outstanding Ordinary Name of Grantees Date of Grant share options Share (US$) share options Share (US$) Cailian Yang July 3, 2021 181,042 2.10 1,448,336 0.2625 November 22, 2021 37,766 3.30 302,128 0.4125 June 5, 2023 30,266 1.63 242,128 0.20375 November 18, 2024 32,000 0.90 256,000 0.1125 Other Employees July 3, 2021 – August 29, 2025 7,435,958 0.1-5.15 59,487,664 0.0125-0.64375 Total – 7,717,032 – 61,736,256 – 2 Adjustments to the Outstanding RSUs Pursuant to the terms and conditions of the 2021 Plan, the number of the outstanding RSUs granted under the 2021 Plan have been adjusted in the following manner with effect from the Effective Date: Before adjustments After adjustments Number of Existing Purchase Price Number of Purchase Price Class B Ordinary of RSUs prior Subdivided Shares of RSUs Shares to be issued to the Share to be issued upon upon Share upon vesting of Subdivision vesting of the Subdivision the outstanding becoming outstanding becoming Name of Grantees Date of Grant RSUs effective RSUs effective Directors Yifan Li March 25, 2026 157,000 Nil 1,256,000 Nil Kai Sun March 25, 2026 157,000 Nil 1,256,000 Nil Shaoqing Xiang March 25, 2026 157,000 Nil 1,256,000 Nil Cailian Yang November 12, 2025 4,000 Nil 32,000 Nil Zhang Yi February 7, 2025 5,953 Nil 47,624 Nil Ren Jia November 12, 2025 7,116 Nil 56,928 Nil Hui Wang March 25, 2026 6,565 Nil 52,520 Nil Employees Other Employees May 30, 2023 – June 12, 2026 1,692,219 Nil 13,537,752 Nil Total – 2,186,853 – 17,494,824 – In accordance with the terms and conditions of the 2021 Plan, the above adjustments in relation to the outstanding Share Options and outstanding RSUs will take effect on the Effective Date. Save for the above adjustments, all other terms and conditions of the 2021 Plan remain unchanged. 3 The Company’s auditors have confirmed in writing that the above pro-rata adjustments made to (a) the exercise price and number of the Subdivided Class B Ordinary Shares falling to be issued upon the exercise of the outstanding share options and (b) the purchase price and number of the Subdivided Class B Ordinary Shares to be issued upon the vesting of the outstanding RSUs are (i) in accordance with the terms and conditions of the 2021 Plan; (ii) satisfy the requirements set out in the supplementary guidance under Rule 17.03(13) of the Hong Kong Listing Rules; and (iii) comply with Appendix 1 to Frequently Asked Questions FAQ13 No.1-20 published by the Stock Exchange. By order of the Board Hesai Group Dr. Yifan Li Chairman of the Board, Executive Director and Chief Executive Officer Hong Kong, July 10, 2026 As at the date of this announcement, the Board comprises: (i) Dr. Yifan Li, Dr. Kai Sun, Mr. Shaoqing Xiang and Ms. Cailian Yang as the executive Directors; and (ii) Ms. Yi Zhang, Mr. Jia Ren and Dr. Hui Wang as the independent non-executive Directors. * For identification purposes only 4